Substantial challenges characterise the management of chronic obstructive pulmonary disease (COPD), including a progressively ...

Treatment with dupilumab is associated with weight gain in about two thirds of adults with atopic dermatitis over 3-6 months, according to a retrospective study.

[A]lthough our findings found that there is insufficient evidence to suggest that dupilumab use is associated with joint pain, the prevalence of joint pain observed among patients treated with ...

Discover a study that highlights dupilumab’s consistent efficacy in eosinophilic oesophagitis, even among patients with ...

Patients with asthma and allergic bronchopulmonary aspergillosis experienced improvements with dupilumab, according to data presented at the American Thoracic Society International Conference.Quality ...

In some patients with chronic obstructive pulmonary disease (COPD), type 2 inflammation may increase exacerbation risk and may be indicated by elevated blood eosinophil counts. Dupilumab, a fully ...

Since its release in 2017, dupilumab (a fully humanized monoclonal antibody that blocks IL-4 and IL-13) has transformed the therapeutic landscape for managing atopic dermatitis (AD) and other ...

Dupilumab reduced the proportion of patients with asthma-exacerbation events, as defined by our protocol, by 87% relative to placebo. Intriguingly, ...

Dupilumab (Dupixent; Sanofi/Regeneron) has been approved to treat moderate to severe AD in children aged 6 months and older as well as in children who have asthma and eosinophilic esophagitis.

Dupilumab is an effective and safe treatment option for patients with atopic dermatitis (AD) in real-life settings, including those with malignancy and other medical comorbidities, ...

Serious adverse events remained rare and skin remained largely clear in adolescents treated with dupilumab (Dupixent) for moderate-to-severe atopic dermatitis (AD) for up to 52 weeks in a phase 3 ...

Dupilumab (Dupixent), a medicine that you get as a shot, is the first new treatment for CSU in the U.S. in over a decade. It’s already used to treat different inflammation conditions in the U.S ...